Triple therapy with first generation HCV protease inhibitors: Lead-in or no lead-in phase?

Journal of Hepatology

Volumn 58, Issue 2, 2013, Pages 391-394

  Pascale, Alina ^a   Serfaty, Lawrence ^a,b  

^a HÔPITAL SAINT ANTOINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Boceprevir; Cost effectiveness; Direct acting antivirals; Rapid virological response; Response guided therapy; Sustained virological response; Telaprevir; Viral resistance

Indexed keywords

BOCEPREVIR; PEGINTERFERON; RIBAVIRIN; TELAPREVIR;

ARTICLE; COST EFFECTIVENESS ANALYSIS; HEPATITIS C; HUMAN; MEDICAL DECISION MAKING; PRIORITY JOURNAL;

EID: 84872410713     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.09.023     Document Type: Note

References (15)

1. EASL Clinical Practice Guidelines Management of hepatitis C virus infection J Hepatol 55 2011 245 264
2. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M. Manns, and M.S. Sulkowski Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
3. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N. Bzowej Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
4. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, and S. Roberts Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
5. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, and S. Zeuzem Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
6. P.Y. Kwo, E.J. Lawitz, J. McCone, E.R. Schiff, J.M. Vierling, and D. Pound Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Lancet 376 2011 705 716
7. J.M. Vierling, S.L. Flamm, and S.C. Gordon Efficacy of boceprevir in prior null responders to peg-interferon-ribavirin: the PROVIDE study Hepatology 54 2011 A931
8. F. Poordad, J.P. Bronowicki, S.C. Gordon, S. Zeuzem, I.M. Jacobson, and M.S. Sulkowski Factors that predict response of patients with HCV infection to boceprevir Gastroenterology 143 2012 608 618
9. C. Moreno, P. Deltenre, J.M. Pawlotsky, J. Henrion, M. Adler, and P. Mathurin Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis J Hepatol 52 2010 25 31
10. A.J. Thomson, A.J. Muir, M.S. Sulkowski, D. Ge, J. Fellay, and K.V. Shianna Interleukin-28B Polymorphism Improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus Gastroenterology 139 2010 120 129
11. V. Leroy, L. Serfaty, M. Bourlière, J.P. Bronowicki, P. Delasalle, and A. Pariente Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver Liver Intern 32 2012 1477 1492
12. C. Camma, S. Petta, M. Enea, R. Bruno, F. Bronte, and V. Capursi Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype1 chronic hepatitis C Hepatology 56 2012 850 860
13. J.P. Bronowicki, C. Hezode, L. Bengtsson, S. Pol, M. Bourlière, and L. Serfaty 100% SVR in IL28B CC patients treated with 12 weeks of telaprevir, peginterferon and ribavirin in the Prove2 trial J Hepatol 56 2012 S430 S431
14. C. Hézode, C. Dorival, F. Zoulim, T. Poynard, P. Mathurin, and S. Pol Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non responders. First results of the French early access program (ANRS CO20-CUPIC) J Hepatol 56 2012 S4
15. F.F. Poordad, E.J. Lawitz, K.R. Reddy, N.H. Afdhal, C. Hezode, and S. Zeuzem A randomized trial comparing ribavirin dose reduction versus erythropoietin for anemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus peginterferon/ribavirin J Hepatol 56 2012 S549 S550